Jaehoon Shim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jaehoon Shim has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Bruce P. Bean
Department of Neurobiology, Harvard Medical School
1 shared publication - Clifford J. Woolf
F.M. Kirby Neurobiology Center, Boston Children's Hospital, Boston, MA, United States
1 shared publication Corey Ray Seehus
Department of Neurobiology Boston Children's Hospital Boston Massachusetts USA
1 shared publicationDongxin Liu
Department of Developmental Cell Biology China Medical University Shenyang China
1 shared publicationDongyi Zhao
Department of Pharmaceutical Toxicology, School of Pharmacy China Medical University Shenyang China
1 shared publication- Feng Guo
Department of Pharmacy, The Fourth Affiliated Hospital of China Medical University, Shenyang, China
1 shared publication
Latest Publications
Increased Na V 1.2 expression and its interaction with CaM contribute to the hyperexcitability induced by prolonged inhibition of CaMKII
Objective: Dysfunction of calcium/calmodulin (CaM)–dependent kinase II (CaMKII) has been involved in hyperexcitability‐related disorders including epilepsy. However, the relationship between CaMKII and neuronal excitability remains unclear. Methods: Neuronal excitability was detected in vivo and in vitro by electroencephalography (EEG), patch clamp and multi‐electrode array (MEA), respectively. Next, we assessed the currents of voltage‐gated sodium channels (VGSCs) by patch clamp, and mRNA and protein expressions of VGSCs were determined by real‐time quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) and western blot, respectively. Meanwhile, the association between the nuclear receptor subfamily 4 group A member 2 ( NR4A2 ) and promoters of Scn2a , was determined by chromatin immunoprecipitation (ChIP)‐qPCR. In addition, we utilized co‐immunoprecipitation (Co‐IP), immunofluorescence labeling, and pull‐down to determine the interaction between VGSCs and CaM. Results: Prolonged CaMKII inhibition by KN93, an inhibitor of CaMKII, for 24 h and CaMKII knockdown induced more seizure‐like events in Wistar rats, TRM rats and C57BL/6 mice, and led to hyperexcitability in primary hippocampal neurons and human induced‐pluripotent stem cell (hiPSC)–derived cortical neurons. In addition, prolonged CaMKII inhibition resulted in elevated persistent sodium current (I NaP )/transient sodium current (I NaT ) and increased mRNA and protein expressions of Na V 1.2. Meanwhile, prolonged CaMKII inhibition by KN93 decreased NR4A2 expression and contributed to a transcriptional repression role of NR4A2 in Scn2a regulation, leading to increased Na V 1.2 expression. Moreover, an increased interaction between Na V 1.2 and CaM was attributable to enhanced binding of CaM to the isoleucine‐glutamine (IQ) domain at the C‐terminus of the Na V 1.2 channel, which may also lead to the potentiation in I NaP /I NaT and channel activity. Furthermore, a peptide that antagonized CaM binding to Na V 1.2 IQ domain (ACNp) rescued hyperexcitability following prolonged CaMKII inhibition. Significance: We unveiled that prolonged CaMKII inhibition induced hyperexcitability through increasing the expression of Na V 1.2 and its association with CaM. Thus, our study uncovers a novel signaling mechanism by which CaMKII maintains appropriate neuronal excitability.
Increased Na V 1.2 expression and its interaction with CaM contribute to the hyperexcitability induced by prolonged inhibition of CaMKII
Objective: Dysfunction of calcium/calmodulin (CaM)–dependent kinase II (CaMKII) has been involved in hyperexcitability‐related disorders including epilepsy. However, the relationship between CaMKII and neuronal excitability remains unclear. Methods: Neuronal excitability was detected in vivo and in vitro by electroencephalography (EEG), patch clamp and multi‐electrode array (MEA), respectively. Next, we assessed the currents of voltage‐gated sodium channels (VGSCs) by patch clamp, and mRNA and protein expressions of VGSCs were determined by real‐time quantitative reverse transcription‐polymerase chain reaction (qRT‐PCR) and western blot, respectively. Meanwhile, the association between the nuclear receptor subfamily 4 group A member 2 ( NR4A2 ) and promoters of Scn2a , was determined by chromatin immunoprecipitation (ChIP)‐qPCR. In addition, we utilized co‐immunoprecipitation (Co‐IP), immunofluorescence labeling, and pull‐down to determine the interaction between VGSCs and CaM. Results: Prolonged CaMKII inhibition by KN93, an inhibitor of CaMKII, for 24 h and CaMKII knockdown induced more seizure‐like events in Wistar rats, TRM rats and C57BL/6 mice, and led to hyperexcitability in primary hippocampal neurons and human induced‐pluripotent stem cell (hiPSC)–derived cortical neurons. In addition, prolonged CaMKII inhibition resulted in elevated persistent sodium current (I NaP )/transient sodium current (I NaT ) and increased mRNA and protein expressions of Na V 1.2. Meanwhile, prolonged CaMKII inhibition by KN93 decreased NR4A2 expression and contributed to a transcriptional repression role of NR4A2 in Scn2a regulation, leading to increased Na V 1.2 expression. Moreover, an increased interaction between Na V 1.2 and CaM was attributable to enhanced binding of CaM to the isoleucine‐glutamine (IQ) domain at the C‐terminus of the Na V 1.2 channel, which may also lead to the potentiation in I NaP /I NaT and channel activity. Furthermore, a peptide that antagonized CaM binding to Na V 1.2 IQ domain (ACNp) rescued hyperexcitability following prolonged CaMKII inhibition. Significance: We unveiled that prolonged CaMKII inhibition induced hyperexcitability through increasing the expression of Na V 1.2 and its association with CaM. Thus, our study uncovers a novel signaling mechanism by which CaMKII maintains appropriate neuronal excitability.
- 10 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (619) , eabj9837
Developing nociceptor-selective treatments for acute and chronic pain
Phenotypic screens using human induced pluripotent stem cell–derived nociceptors hold promise for the development of better analgesics.
- 10 November 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (619) , eabj9837
Developing nociceptor-selective treatments for acute and chronic pain
Phenotypic screens using human induced pluripotent stem cell–derived nociceptors hold promise for the development of better analgesics.